Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Inclusion Criteria: * Patients with histologically confirmed classical HL that is relapsed or refractory after at least one prior therapy are eligible * Patients with lymphocyte predominant Hodgkin's are eligible * Prior treatments: patients must have had at least one prior therapy * Patients with previous autologous transplant are permitted * Patients who are eligible and willing to undergo autologous transplant should not be enrolled on this trial * Prior allogeneic transplant is NOT permitted * Prior treatment with Bruton's tyrosine kinase (BTK) inhibitors is NOT permitted * Prior treatment with nivolumab is permitted * Presence of radiographically measurable disease (defined as the presence of a \>= 1.0 cm lesion, as measured in the longest dimension by computed tomography \[CT\] scan or positron emission tomography \[PET\]/CT scan or magnetic resonance imaging \[MRI\] scan) * Absolute neutrophil count (ANC) \> 1000/uL * Platelets \> 75,000/uL * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2 x upper limit of normal (ULN) * Total bilirubin =\< 1.5 x ULN * Creatinine =\< 2.0 mg/dl * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 * Patients with human immunodeficiency virus (HIV) are not permitted to enroll * Patients with history of hepatitis B or C infection are not permitted to enroll; to enroll patients must have no evidence of hepatitis B or C surface antigen (Ag) and negative hepatitis B core antibody (Ab…